162 Shareholder Information The information in this Shareholder Information section is current as at 31 July 2026. CSL Limited Issued Capital Ordinary Shares: 478,911,979 as at 30 June 2026; 478,911,979 as at 31 July 2026. Details of incorporation CSL’s activities were carried on within the Commonwealth Department of Health until the Commonwealth Serum Laboratories Commission was formed as a statutory commission pursuant to the Commonwealth Serum Laboratories Act 1961 (Cth) (the CSL Act) on 2 November 1961. On 1 April 1991, the statutory commission was converted to a public company limited by shares under the Corporations Law of the Australian Capital Territory, and it was renamed Commonwealth Serum Laboratories Limited. These changes were brought into effect by the Commonwealth Serum Laboratories (Conversion into Public Company) Act 1990 (Cth). On 7 October 1991, the name was changed to CSL Limited. The Commonwealth divested all of its shares by public float on 3 June 1994. The CSL Sale Act 1993 (Cth) amended the CSL Act to impose certain restrictions on the voting rights of persons having significant foreign shareholdings, and certain restrictions on CSL itself. CSL ordinary shares (being the only class of shares on issue) have been traded on the Australian Securities Exchange (ASX) under the ticker code – CSL, since 30 May 1994. In June 2014, CSL commenced a sponsored Level 1 American Depositary Receipts (ADR) program. The sponsored ADR program replaced the unsponsored ADR programs that previously operated with CSL’s involvement. The American Depositary Receipts are traded on the over-the-counter (OTC) securities market in the United States. The American Depositary Shares are tradeable via licensed US brokers in the ordinary course of trading in the OTC market in the United States. Particulars for the sponsored ADR program are: US Exchange – OTC, and DR ticker symbol – CSLLY. Substantial shareholders The following table shows (as at 31 July 2026) the details of each substantial shareholder who, together with their associates, notified CSL Limited under section 671B of the Corporations Act 2001 (Cth) that they hold 5% or more of voting rights in CSL Limited’s shares. Date of last notice Title of class Identity of person or group Date received Date of change Number owned Ordinary shares Vanguard Group 29 January 2026 23 January 2026 29,109,134 Ordinary shares State Street Group 7 May 2026 5 May 2026 39,466,383 Ordinary shares BlackRock Group 3 June 2026 29 May 2026 33,347,498* * In addition to 33,347,498 ordinary shares, BlackRock Group also holds 396,757 ADRs. Voting rights Ordinary shares At a general meeting, subject to restrictions imposed on significant foreign shareholdings and some other minor exceptions, on a show of hands, each shareholder present has one vote. On a poll, each shareholder present in person or by proxy, attorney or representative has one vote for each fully paid share held. In accordance with the CSL Act, CSL’s Constitution provides that the votes attaching to significant foreign shareholdings are not to be counted when they pertain to the appointment, removal or replacement of any ‘A class’ designated Director of CSL who holds office at any particular time. A significant foreign shareholding is one where a foreign person has a relevant interest in 5% or more of CSL’s voting shares. As noted above, CSL has an American Depositary Receipts (ADR) program for CSL Limited, with four ADRs representing one ordinary share in CSL. Holders of ADRs therefore have one vote for every four ADRs held. ADR voting is managed by Deutsche Bank Shareholder Services.
RkJQdWJsaXNoZXIy MjE2NDg3